导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.54% | 3211/4776 |
| 近一周 | -1.04% | 1877/5469 |
| 近一月 | -1.09% | 3596/5402 |
| 近一季 | 11.41% | 225/5194 |
| 近半年 | 2.00% | 1629/4906 |
| 近一年 | -12.05% | 3843/4331 |
| 近两年 | 15.41% | 2715/2948 |
| 近三年 | -9.04% | 2015/2226 |
| 成立以来 | -15.16% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.66% 2418/4961 |
-6.46% 3700/5312 |
- - |
- - |
| 2025 | 5.39% 3002/4813 |
0.83% 1758/3635 |
2.12% 1853/4076 |
16.41% 2654/4524 |
-12.07% 4241/4813 |
| 2024 | -12.66% 2387/3463 |
-10.72% 2371/2808 |
-9.00% 2311/3014 |
18.72% 951/3129 |
-9.45% 2928/3463 |
| 2023 | -10.29% 1283/2656 |
0.37% 1738/2280 |
-7.80% 1916/2385 |
-0.99% 473/2515 |
-2.09% 423/2655 |
| 2022 | -19.69% 885/2207 |
-12.24% 594/1919 |
0.26% 1569/2016 |
-16.62% 1481/2113 |
9.46% 218/2208 |
| 2021 | -5.06% 970/1822 |
-1.60% 521/1255 |
16.40% 204/1330 |
-13.42% 1342/1466 |
-4.26% 1474/1822 |
| 2020 | - - |
- - |
- - |
7.78% 761/1164 |
7.23% 724/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 东财医药C VS. 长安沪深300非周期A(740101) |